Atlas Trials

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Clinical trial NCT04181762 · TERMINATED

Trial details

NCT number
NCT04181762
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Lupus Nephritis
Start date
2020-07-07
Primary completion
2023-09-13
Enrollment
275

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.